Latest Technology Platforms News

Mesoblast Limited posted US$30.3 million in net revenues for Ryoncil® in Q3 2026, hitting key clinical milestones and securing new technology licenses that could boost its next-generation cell therapies.

CurveBeam AI reported stable device orders but faces regulatory delays for FDA and China clearances, while securing a A$4 million investment from WEGO Orthopaedics and advancing clinical collaborations with robotic surgery systems.

Zeotech pushed forward its AusPozz™ metakaolin commercialisation with extended and new MOUs, progressed key Toondoon project approvals amid rising contractor costs, and launched live methane control trials.

ANZ moves to fully own the ANZ Worldline joint venture by acquiring Worldline S.A’s 51% share for $89 million, aiming to deepen its transaction banking services as part of its 2030 strategy.

Nexsen Limited has cleared a major FDA regulatory hurdle for its StrepSure rapid Group B Streptococcus test, confirmed a clear 510(k) submission pathway, and secured over A$1.7 million in non-dilutive grants to expand clinical validation and market rollout in Asia-Pacific and neonatal diagnostics.

Way2VAT reported a 95% surge in Q1 FY26 revenue to $2.05 million, driven by its RBC acquisition and expanding client base, while preparing to launch an e-invoicing platform integrating AI-powered APAI technology.

Butn Limited has signed a memorandum of understanding with a major global bank to launch buyer-led supply chain finance programs in Australia, leveraging Butn’s proprietary platform and the bank’s funding capacity.

Firebird Metals has locked in exclusive global rights to key LMFP patents through 2045 and commissioned lithium-manganese-rich cathode equipment, progressing its Australian Demonstration Plant with a $2 million ARENA grant.

Adisyn has confirmed a major graphene breakthrough compatible with semiconductor manufacturing and secured exclusive radar absorption rights, backed by a $14 million placement led by top institutional investors.

Ovanti Limited is issuing a bonus tranche of Loyalty Options to shareholders at no cost, exercisable at a modest $0.025, potentially raising close to $1 million if fully converted.

Adisyn Ltd has landed a A$14 million placement led by heavyweight institutional investors following two major graphene technology milestones in semiconductors and stealth drone materials.

Noxopharm reports preclinical data revealing SOF-SKN’s active ingredient remains in skin tissues for about 3.5 days with minimal systemic absorption, supporting less frequent dosing and sustained activity for cutaneous lupus treatment.